Idogen publishes interim report for 1 January – 30 September 2022

REGULATORISK

 

Idogen AB's interim report for January to September 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/

 

Second quarter (July-September 2022)

 Other operating income amounted to KSEK 0 (7,171)

• Operating loss was KSEK -14,343 (-5,249)

• Loss for the quarter totalled KSEK -14,398 (-5,191)

• Cash flow from operating activities was KSEK -9,879 (-9,029)

• Loss per share before dilution was SEK -0.20 (-0.28). Loss per share after dilution was SEK -0.20 (-0.28)

 

Period (January-September 2022)

• Other operating income amounted to KSEK 159 (10,580)

• Operating loss was KSEK -36,212 (-25,413)

• Loss for the quarter totalled KSEK -36,286 (-25,326)

• Cash flow from operating activities was KSEK -38,111 (-25,116)

• Loss per share before dilution was SEK -0.58 (-1.39). Loss per share after dilution was SEK -0.58 (-1.39)

 

Significant events in the third quarter

• Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.

• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.

• An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new

chairman and Niklas Wallet as a new member of the Board of Directors.

• Christina Herder is appointed acting CEO after Anders Karlsson.

 

Significant events in the period

• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.

• Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune

Tolerance Summit.

• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.

• Idogen’s rights issue raise MSEK 41 after issue costs.

• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study

for IDO 8.

• Idogen’s rights issue raise MSEK 41 after issue costs.

• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

• Idogen strengthens the organization with key competencies for the clinical development phase.

 

 

Significant events after the end of the period

• Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.

• Idogen receives after exercise of warrants 280 KSEK before costs.

• First patient enters Idogen’s hemophilia study under the IDO 8 program.

• EU to disburse the remaining of the Horizon 2020 grant.

• Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.

• The board of Idogen propose a rights issue at up to 38 MSEK net after cost.

• Idogen invites for an extra shareholder meeting 13 December

• No other significant events occurred after the end of the period that affected the results or financial position.

 

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70 374 71 56

E-mail: christina.herder@idogen.com

 

 

Certified Adviser:
Vator Securities AB

 

 

The information was submitted for publication, through the agency of the contact persons set out above, on November 25, 2022 at 08:03 CET.

 

 

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

 

 

Bifogat dokument